| 產(chǎn)品編號(hào) | bs-0525R-HRP |
| 英文名稱 | Rabbit Anti-Thrombomodulin/HRP Conjugated antibody |
| 中文名稱 | 辣根過氧化物酶標(biāo)記的血栓調(diào)節(jié)蛋白抗體 |
| 別 名 | Thrombomodulin; CD 141; CD141; CD141 antigen; Fetomodulin; THBD; THRM; TM; AHUS 6; AHUS6; BDCA 3; BDCA3; THPH12; TRBM_HUMAN. |
 |
Journal
PMID
IF
Application
[IF=4.497] Ikezoe et al. The fifth epidermal growth factor-like region of thrombomodulin exerts cytoprotective function and prevents SOS in a murine model. (2017) Bone.Marrow.Transplant. 52:73-79 ELISA ; Mouse.
|
| 規(guī)格價(jià)格 | 100ul/2980元 購(gòu)買 大包裝/詢價(jià) |
| 說 明 書 | 100ul |
| 研究領(lǐng)域 | 心血管 細(xì)胞生物 神經(jīng)生物學(xué) 血管內(nèi)皮細(xì)胞 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | Human, (predicted: Mouse, Rat, Dog, Cow, ) |
| 產(chǎn)品應(yīng)用 | WB=1:500-2000 ELISA=1:100-1000 IHC-P=1:50-200 IHC-F=1:50-200 ICC=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 61kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from mouse Thrombomodulin |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲(chǔ) 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: Thrombomodulin, TM is cell surface glycoprotein; plays an important role in the protein C anticoagulant pathway. It located in a vein, artery and capillary endothelial cells on the surface of plasma membrane protein. It is generally believed: TM vascular endothelial injury is an important parameter is the thrombin receptor, known in a variety of normal human tissues, can also be expressed in many tumors, TM may be similar to the E-cadherin,and is a lectin Like activity of a new class of members of the cell adhesion molecules. CD141/Thrombomodulin is an exclusively endothelial cell surface glycoprotein that forms a 1:1 complex with thrombin. Binding of thrombin to this high-affinity receptor alters its specificity toward several substrates. The complex activates protein C approximately 1000 times faster than thrombin alone. Activated protein C degrades clotting factors V and VIII; thus, thrombomodulin converts thrombin into a physiologic anticoagulant. Thrombomodulin is also found in the circulatory and urinary systems, the physiologic significance of this is obscure. Function: Thrombomodulin is a specific endothelial cell receptor that forms a 1:1 stoichiometric complex with thrombin. This complex is responsible for the conversion of protein C to the activated protein C (protein Ca). Once evolved, protein Ca scissions the activated cofactors of the coagulation mechanism, factor Va and factor VIIIa, and thereby reduces the amount of thrombin generated. Subcellular Location: Membrane; Single-pass type I membrane protein. Tissue Specificity: Endothelial cells are unique in synthesizing thrombomodulin. Post-translational modifications: N-glycosylated. The iron and 2-oxoglutarate dependent 3-hydroxylation of aspartate and asparagine is (R) stereospecific within EGF domains. DISEASE: Defects in THBD are the cause of thrombophilia due to thrombomodulin defect (THPH12) [MIM:614486]. A hemostatic disorder characterized by a tendency to thrombosis. Defects in THBD are a cause of susceptibility to hemolytic uremic syndrome atypical type 6 (AHUS6) [MIM:612926]. An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Note=Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype. Similarity: Contains 1 C-type lectin domain. Contains 6 EGF-like domains. Database links: Entrez Gene: 7056 Human Omim: 188040 Human SwissProt: P07204 Human Unigene: 2030 Human Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 血栓調(diào)節(jié)蛋白(thrombomodulin,TM)是一種分布于靜脈、動(dòng)脈和毛細(xì)血管內(nèi)皮細(xì)胞表面的質(zhì)膜蛋白。 一般認(rèn)為：TM是血管內(nèi)皮損傷的重要參數(shù)，也是凝血酶的受體，已知在人類多種正常組織中表達(dá)，亦可表達(dá)于許多腫瘤組織，TM可能類似于鈣粘蛋白，是具有凝集素樣活性的新一類細(xì)胞粘附分子的成員。TM是血管內(nèi)皮細(xì)胞膜上的凝血酶受體之一。與凝血酶結(jié)合后可降低凝血酶的凝血活性，而加強(qiáng)其激活蛋白C的活性。由于被激活的蛋白C具有抗凝作用，因此，TM是使凝血酶由促凝轉(zhuǎn)向抗凝的重要的血管內(nèi)凝血抑制因子。 |
